In a report released yesterday, Robert Hazlett from BTIG maintained a Buy rating on Galera Therapeutics (GRTX), with a price target of $30.00. The company’s shares closed last Wednesday at $6.61, close to its 52-week low of $6.15.
According to TipRanks.com, Hazlett is a 5-star analyst with an average return of 36.7% and a 49.4% success rate. Hazlett covers the Healthcare sector, focusing on stocks such as TRACON Pharmaceuticals, Seelos Therapeutics, and Homology Medicines.
Galera Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $20.00, which is a 211.0% upside from current levels. In a report issued on April 26, Credit Suisse also initiated coverage with a Buy rating on the stock with a $15.00 price target.
See today’s analyst top recommended stocks >>
Based on Galera Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $20.07 million. In comparison, last year the company had a GAAP net loss of $16.67 million.
Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Galera Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on the prevention of radiation-induced toxicity, including mucositis and the treatment of fibrosis and cancer. The company was founded by Robert A. Beardsley, Randy W. Weiss, and Dennis P. Riley in 2009 and is headquartered in Malvern, PA.
